ArticleJournal of virology2007
Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus.
Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Comparative analyses for plant virus-based cancer immunotherapy drug development.Cell biomaterials · 2025Article
- Single-Point Mutations in Qβ Virus-like Particles Change Binding to Cells.Biomacromolecules · 2021Article
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
- The unique potency of Cowpea mosaic virus (CPMV)Biomaterials science · 2020Article
- Affinity of plant viral nanoparticle potato virus X (PVX) towards malignant B cells enables cancer drug delivery.Biomaterials science · 2020Article
- Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes.Beilstein journal of nanotechnology · 2020Article
- Delivery of mitoxantrone using a plant virus-based nanoparticle for the treatment of glioblastomas.Journal of materials chemistry. B · 2018Article
- Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology.Advances in virus research · 2017Review
- Utilizing Viral Nanoparticle/Dendron Hybrid Conjugates in Photodynamic Therapy for Dual Delivery to Macrophages and Cancer Cells.Bioconjugate chemistry · 2016Article
- Article
- Interface of physics and biology: engineering virus-based nanoparticles for biophotonics.Bioconjugate chemistry · 2015Article
- Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Design rules for nanomedical engineering: from physical virology to the applications of virus-based materials in medicine.Journal of biological physics · 2013Review
- Endocytic uptake pathways utilized by CPMV nanoparticles.Molecular pharmaceutics · 2013Article
- Differential uptake of chemically modified cowpea mosaic virus nanoparticles in macrophage subpopulations present in inflammatory and tumor microenvironments.Biomacromolecules · 2012Article
- Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions.Nanomedicine (London, England) · 2012Article
- Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors.Small (Weinheim an der Bergstrasse, Germany) · 2011Article
- Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting.Nano letters · 2010Article
- Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties.Nano letters · 2009Article
- Interaction of Cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cowpea mosaic virus (CPMV), a plant virus that is a member of the picornavirus superfamily, is increasingly being used for nanotechnology applications, including material science, vascular imaging, vaccine development, and targeted drug delivery. For these applications, it is critical to understand the in vivo interactions of CPMV within the mammalian system. Although the bioavailability of CPMV in the mouse has been demonstrated, the specific interactions between CPMV and mammalian cells need to be characterized further. Here we demonstrate that although the host range for replication of CPMV is confined to plants, mammalian cells nevertheless bind and internalize CPMV in significant amounts. This binding is mediated by a conserved 54-kDa protein found on the plasma membranes of both human and murine cell lines. Studies using a deficient cell line, deglycosidases, and glycosylation inhibitors showed that the CPMV binding protein (CPMV-BP) is not glycosylated. A possible 47-kDa isoform of the CPMV-BP was also detected in the organelle and nuclear subcellular fraction prepared from murine fibroblasts. Further characterization of CPMV-BP is important to understand how CPMV is trafficked through the mammalian system and may shed light on how picornaviruses may have evolved between plant and animal hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.